Rockefeller Capital Management
CYTK icon

Rockefeller Capital Management’s Cytokinetics CYTK Stock Holding History

Rockefeller Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Buy
3,183
+314
+11% +$22.5K ﹤0.01% 2437
2026
Q1 		$189K Buy
2,869
+2,228
+348% +$142K ﹤0.01% 2534
2025
Q4 		$40.7K Buy
641
+573
+843% +$35.6K ﹤0.01% 3160
2025
Q3 		$3.74K Buy
+68
New +$2.8K ﹤0.01% 3959
2023
Q1 		– Sell
-31
Closed -$1K – 2410
2022
Q4 		$1K Hold
31
– – ﹤0.01% 3665
2022
Q3 		$1K Sell
31
-98
-76% -$4.72K ﹤0.01% 3692
2022
Q2 		$5K Buy
129
+117
+975% +$4.71K ﹤0.01% 3435
2022
Q1 		$0 Buy
+12
New +$426 ﹤0.01% 3898
2021
Q3 		– Sell
-100
Closed -$1K – 3713
2021
Q2 		$1K Sell
100
-600
-86% -$14.1K ﹤0.01% 3324
2021
Q1 		$16K Hold
700
– – ﹤0.01% 2376
2020
Q4 		$14K Buy
700
+300
+75% +$5.48K ﹤0.01% 2130
2020
Q3 		$8K Buy
+400
New +$9.36K ﹤0.01% 2072

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's CYTK Position: Q2 2026 in Review

Rockefeller Capital Management increased its Cytokinetics (CYTK) stake by 11% in Q2 2026, buying an estimated $22.5K and bringing the position to 3,183 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #2437.

Rockefeller Capital Management first reported a position in CYTK in Q3 2020 and has held it in 12 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Rockefeller Capital Management held 3,183 shares of Cytokinetics worth $271K as of Q2 2026.
  • Rockefeller Capital Management bought 314 Cytokinetics shares in Q2 2026, an estimated $22.5K.
  • Cytokinetics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2437 holding.
  • Rockefeller Capital Management first reported a position in Cytokinetics in Q3 2020 and has held it in 12 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.